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Abstract
Background: Peripheral artery disease (PAD) is caused by atherosclerotic occlusions in the legs. It affects approximately 8-12
million people in the United States alone, one-third of whom suffer from intermittent claudication (IC), defined as ischemic leg
pain that occurs with walking and improves with rest. Patients with IC suffer a markedly impaired quality of life and a high
perception of disability. Improving pain-free walking time is a primary goal of rehabilitation in this population.
Objective: The nitric oxide (NO)-PAD trial is designed to compare the effects that 12 weeks of supervised exercise training,
in combination with a high inorganic nitrate-content (beetroot [BR] juice) beverage or placebo (PL) beverage, has on clinical
outcomes of exercise and functional capacity in two groups of PAD+IC patients: exercise training plus beetroot (EX+BR) and
exercise training plus placebo (EX+PL). The primary aims of this randomized controlled, double-blind pilot study are to determine
group differences following 12 weeks of EX+BR versus EX+PL in the changes for (1) exercise capacity: pain-free walking time
(claudication onset time, COT), peak walk time (PWT), and maximal exercise capacity (peak oxygen uptake, VO2peak) during a
maximal-graded cardiopulmonary exercise test (max CPX) and (2) functional capacity: 6-minute walk (6MW) distance. The
secondary aims will provide mechanistic insights into the exercise outcome measures and will include (1) gastrocnemius muscle
oxygenation during exercise via near-infrared spectroscopy (NIRS); (2) gastrocnemius muscle angiogenesis: capillaries per unit
area and per muscle fiber, and relative fraction of type I, IIa, IIb, and IId/x fibers; and (3) vascular health/function via brachial
artery flow-mediated dilation, lower-limb blood flow via plethysmography, and pulse wave velocity and reflection.
Methods: A total of 30 subjects between 40 and 80 years of age with PAD who are limited by IC will undergo exercise training
3 days per week for 12 weeks (ie, 36 sessions). They will be randomized to either the EX+BR or EX+PL group where participants
will consume a beverage high in inorganic nitrate (4.2 mmol) or a low-nitrate placebo, respectively, 3 hours prior to each training
session.
Results: Data collection from this study has been completed and is in the process of analysis and write-up. While the study is
too underpowered—EX+BR, n=11; EX+PL, n=13—to determine between-group differences in the primary outcomes of COT,
PWT, and 6MW, preliminary observations are promising with Cohen d effect sizes of medium to large.
Conclusions: Exercise training is currently the most effective therapy to increase functional capacity in PAD+IC. If the addition
of inorganic nitrate to an exercise regimen elicits greater benefits, it may redefine the current standard of care for PAD+IC.
Trial Registration: ClinicalTrials.gov NCT01684930; https://clinicaltrials.gov/ct2/show/NCT01684930 (Archived by WebCite
at http://www.webcitation.org/6raXFyEcP)
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Introduction
Peripheral artery disease (PAD) is caused by stenosis of the
arteries in the lower limbs, leading to a reduction in blood flow
to the legs [1]. It affects approximately 8-12 million people
within the United States alone, one-third of whom suffer from
intermittent claudication (IC), defined as ischemic leg pain that
occurs with walking and improves with rest [2]. Patients with
IC suffer a markedly impaired quality of life and a high
perception of disability [3]. Consequently, improving pain-free
walking time is an important clinical goal for these patients [4].
Thus far, interventions aimed at improving clinical outcomes
in patients with PAD have been either surgical, pharmacological,
or exercise based, with supervised exercise training identified
as the current best intervention for improving functional
outcomes such as peak walking time and pain-free walking time
[5-7]. Exercise training has proven efficacy in improving
vascular health and function for atherosclerosis-associated
comorbidities such as obesity, hypertension, dyslipidemia, and
type 2 diabetes mellitus [8-14]. Patients with PAD have marked
impairments in the oxygen delivery and uptake pathway due to
deficiencies in both vascular function—increased arterial
stiffness, endothelial dysfunction, and decreased peripheral
blood flow—and skeletal muscle composition and
architecture—capillary density rarefaction, mitochondrial
dysfunction, and a loss of oxidative (ie, slow-twitch) fibers
[15-18]. As they result in a more glycolytic phenotype leading
to earlier onset of fatigue and exhaustion, the skeletal muscle
abnormalities have a detrimental effect on the delivery, uptake,
and utilization of oxygen. While supervised exercise training
can improve both the skeletal abnormalities [19] and vascular
function [20] in these patients, improving the patient’s ability
to acutely tolerate an exercise bout could lead to even greater
efficacy in the exercise training intervention by allowing them
to exercise at a greater intensity at each session. Thus, to identify
the next best treatment for patients with PAD, there is a
continued need to advance our current understanding of both
the disease and optimal interventional therapies.
Dysfunction of the vascular endothelium is a hallmark of
cardiovascular diseases, including PAD [21]. A key facet of
this dysfunction is abnormal vessel reactivity, which is mediated
in part by a reduction in nitric oxide (NO) production [22]. NO
is diatomic free radical that plays an important role in
modulating vascular tone and regulating blood flow. In healthy
individuals, NO is produced endogenously by endothelial nitric
oxide synthase in response to elevated shear stress at the arterial
wall. Patients with cardiovascular disease, in particular those
with PAD, lack the ability to endogenously increase vascular
NO bioavailability, leading to significant dysfunctions within
the vasculature.
Plasma nitrite (NO2
-), while once considered to be a biologically
inert marker of NO, has recently been identified as an alternative
NO source that can be reduced to NO under low oxygen
conditions, such as hypoxia or ischemia [23]. One established
noninvasive mechanism for increasing plasma NO2
- is via oral
consumption of inorganic nitrate (NO3
-). Inorganic NO3
- is
found in relatively high concentrations in green leafy vegetables
and beetroot. When swallowed, inorganic NO3
- is rapidly
absorbed in the small intestine and while a majority is excreted
by the kidneys, up to 25% is retained and becomes concentrated
in the salivary glands. When the saliva is secreted, commensal
oral bacteria on the dorsal surface of the tongue reduce the NO3
-
to NO2
-, which is then swallowed and absorbed back into the
circulation. NO2
- concentration peaks approximately 2.5-4 hours
after inorganic NO3
- consumption [24,25]. The circulating NO2
-
is further reduced to NO in hypoxic conditions; the NO3
-
-NO2
--NO reduction pathway increases peripheral blood flow
during exercise and leads to improvements in exercise tolerance.
NO3
- supplementation has shown mixed effects on exercise
performance [26-30]. In healthy and athletic populations, NO3
-
supplementation has decreased the oxygen cost of exercise
[28,31], increased time to exhaustion [28], and improved time
trial performance [26]. However, studies utilizing similar
participant demographics have reported no effect of NO3
-
supplementation on power output [32], time trial time [33], or
submaximal exercise efficiency [34]. One proposed explanation
for these mixed findings is the discovery that an individual’s
level of aerobic fitness could impact the effectiveness of nitrate
supplementation, with one study demonstrating reductions in
the oxygen cost of exercise and improvements in time trial
performance only in participants with a low-moderate level of
aerobic fitness [35]. While this research into responders and
nonresponders to nitrate supplementation is still in the early
stages, this particular finding perhaps lends more support for
nitrate supplementation’s potential efficacy in clinical
populations with low aerobic capacity. Indeed, in clinical
populations, most of the results have been positive:
improvements in submaximal endurance, muscle contractile
function, and exercise capacity in heart failure [36-38], as well
as submaximal exercise endurance in chronic obstructive
pulmonary disease [39]. Only a few studies showed no effect
[40]. In patients with PAD, following a single acute dose of a
high-nitrate-containing beetroot (BR) juice (18 mmol), which
led to a five-fold increase in plasma nitrite in comparison to
placebo (PL) [27], we have previously shown an 18% and 17%
increase in treadmill walking claudication onset time (COT)
and peak walk time (PWT), respectively. While initial results
show promise, most of the studies have utilized acute dosing
strategies and have been limited in both sample size and
demographic diversity.
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While exercise training is the current best intervention for
patients with PAD, by allowing the patients to acutely train at
higher intensities—due to improvements in oxygen
delivery/uptake—resulting in a greater cumulative effect than
exercise alone, the acute benefits of nitrate supplementation on
exercise tolerance suggest a potential opportunity to further
enhance the effects of exercise training [6].
The hypothesis of this study is that subjects with peripheral
artery disease with intermittent claudication (PAD+IC) who
undertake regular consumption of a high-inorganic nitrate (4.2
mmol) supplement in conjunction with 12 weeks of supervised
exercise training (exercise training plus beetroot juice [EX+BR])
will experience a greater clinical benefit in pain-free walking
time (COT, 6-minute walk [6MW]) and PWT than those
undertaking exercise and a placebo beverage (exercise training
plus placebo juice [EX+PL]) alone. Specifically, the primary
aim of this study is to determine group differences (EX+BR vs
EX+PL) in the changes in the following:
1. Exercise capacity: pain-free walking time (COT), PWT,
and maximal exercise capacity/peak oxygen uptake
(VO2peak) during a maximal-graded cardiopulmonary
exercise test (max CPX).
2. Functional capacity: 6MW distance.
Secondary aims designed to provide mechanistic insight into
the exercise outcomes include the following:
1. Gastrocnemius tissue oxygenation during max CPX testing
via near-infrared spectroscopy (NIRS).
2. Gastrocnemius muscle angiogenesis: capillaries per unit
area and per muscle fiber, and relative fraction of type I,
IIa, IIb, and IId/x fibers.
3. Vascular health/function via brachial artery flow-mediated
dilation, lower-limb blood flow via plethysmography, and
pulse wave velocity (PWV) and reflection.
Methods
Study Design
The NO-PAD trial is a pilot, randomized, double-blind,
per-protocol design with four different assessment time points
(see Figure 1). This study is registered with ClinicalTrials.gov
(NCT01785524).
The first round of assessment will act as a baseline with no
exercise intervention or supplementation. Following this, all
participants will be randomized to groups consuming either a
70 mL (4.2 mmol nitrate) beetroot juice (Beet It, James White
Drinks Ltd, Ipswich, UK) or an identical nitrate-depleted
placebo. Participants will then repeat the baseline assessments,
except for the muscle biopsy, but will consume their assigned
beverage 3 hours prior to each visit.
Participants will continue consuming their beverage 3 hours
prior to each of their 36 exercise training sessions. Periodically,
subjects will be selected for unannounced blood draws at
training visits to check plasma nitrate and nitrite concentrations.
Post-exercise training, participants will complete the same
assessments as the baseline visit while still acutely consuming
their beverage before visits. Both groups will then stop
consuming the beverage for at least 1 week prior to the final
visit. The half-life of nitrate is 5-8 hours and as the
supplementation protocol is three acute doses per week, a
1-week washout period should be sufficient to minimize any
possible residual effect of the nitrate [41]. To maximize internal
validity, study personnel, time of day, equipment, and order of
testing will be consistent for each of the assessment time points.
Figure 1. Study design with visit timeline and corresponding assessments. 6MW: 6-minute walk; BR: beetroot juice; COT: claudication onset time;
max CPX: maximal-graded cardiopulmonary exercise test; NIRS: near-infrared spectroscopy; PL: placebo juice; PWT: peak walk time; VO2peak: peak
oxygen uptake.
Recruitment Strategies and Eligibility
We aim to recruit a total of 30 participants—equal numbers of
men and women—between the ages of 40 and 80 years with
diagnosed PAD from the clinics and community at Duke
University Medical Center. We anticipate a dropout rate of
approximately 15%-20% and, therefore, 24 patients out of the
30 (EX+BR, n=12; EX+PL, n=12) are expected to complete
the study. This study will have continuous rolling enrollment
until the recruitment goals are met. Subjects will be recruited
primarily through collaboration with Duke University Medical
Center cardiovascular physicians and vascular surgeons. Clinic
medical records will be reviewed to prescreen patients for
inclusion and exclusion criteria (see Textbox 1).
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Textbox 1. Inclusion and exclusion criteria for study screening visit.
Inclusion criteria:
1. Aged between 40 and 80 years.
2. Diagnosed peripheral artery disease (ankle-brachial index <0.90) with intermittent claudication.
3. No major changes in medications for at least 3 months.
Exclusion criteria:
1. Foot ulcers, advanced neuropathy, gangrene, or other musculoskeletal condition that could limit exercise performance.
2. Type 1 diabetes or glycated hemoglobin >8.5%.
3. A major cardiovascular event within the previous 6 weeks or a planned hospitalization within the next 2 months.
4. Any cardiovascular condition that impacts safety of completing a cardiopulmonary exercise test, including history of significant left main or
three-vessel coronary artery disease (>70% stenosis), recent myocardial infarction (6 weeks), chest pain during cardiopulmonary exercise test, or >2
mm ST depression during exercise; foot ulcers/advanced neuropathy or other musculoskeletal condition that could limit exercise performance.
5. Allergy to beets or proton pump inhibitors.
6. Refusal or inability to abstain from the use of proton pump inhibitors for 24 hours prior to testing.
Records of those criteria will be noted and the appropriate
medical doctor will introduce the study to the patient. Patients
who consent to being contacted by the research team will
undergo a telephone screening questionnaire to determine if the
study eligibility criteria are met. Eligible and interested patients
will then attend an orientation visit and a consent meeting.
During this initial visit, the study details will be explained
verbally and the individuals will have the opportunity to read
over the approved informed consent document and ask any
questions they may have about the trial. The patients can then
choose to sign the informed consent form or decline
participation. Following the consent visit, enrolled subjects will
return on a separate day to undergo a physical examination and
a review of their medical history and medications by the study
physician. Participants will then be scheduled for their baseline
assessment visits. Details of the testing occurring at each time
point is outlined in Figure 1 and is described in detail in the
Testing Methodology section.
Supplementation
Following initial screening and baseline testing, subjects will
be randomized to consume either a high-nitrate-containing
beetroot beverage or a low-nitrate placebo throughout the
duration of the exercise training. Randomization should ensure
the groups are initially equal within either the EX+BR or EX+PL
intervention. Both groups will be instructed to consume one 70
mL bottle of beetroot juice (containing 4.2 mmol inorganic
nitrate) 2.5-3 hours prior to every testing visit and training
session between time point 2 and time point 3. The beetroot
juice bottles will be identical in appearance and taste. The bottles
will be color coded by a third party to ensure that the research
staff remain blinded while providing the correct supplement to
each participant.
Scheduled but unannounced blood draws will be performed
throughout the study to confirm participants are conforming to
their appropriate beverage allocations.
Exercise Intervention
Overall Program and Attendance Requirements
All subjects will attend supervised exercise training sessions
three times per week for a total of 12 weeks at the Duke Health
and Fitness Center at the Duke University Medical Center for
Living. Each session is structured to last approximately 45-60
minutes, including taking vital signs—heart rate and blood
pressure (BP)—before and after the training session. To meet
minimum exercise session attendance requirements, participants
will need to complete 34 of the 36 exercise training sessions
and should not miss more than 1 week of training (ie, 3 sessions)
consecutively. Additional sessions will be added if necessary
to ensure that an adequate exercise stimulus is given to each
subject so that any decreases in fitness or function during
unintended breaks are mitigated. The study will be analyzed
under per-protocol criteria. Subjects who withdraw from the
study prior to completion will be excluded from the final
analysis. However, attrition rates will be reported and
documented.
Participants will not be excluded due to current exercise habits,
but all participants will be instructed to maintain their normal
activity levels throughout the exercise intervention.
Training Details
The exercise session will consist of approximately 5 minutes
of warm-up, 30 minutes of accumulated exercise (not including
rest periods), and cooldown (if necessary). The walking treadmill
exercise prescription is individualized to each participant’s
exercise capacity during baseline testing and their rate of
progression. The protocol requires participants to accumulate
a total of 30 minutes of walking with claudication pain. Neither
rest time nor time spent exercising before pain onset will count
toward the 30-minute goal. The patient will be encouraged to
continue walking as far as they can, but will self-select when
they require a rest break. Exercise and rest periods are repeated
during each session until the minimum total of 30 minutes of
walking time is reached each session. When a patient can walk
8-10 minutes at the initial workload, the grade will be increased
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by 0.5%, or the speed increased by 0.1 mph as tolerated, to
ensure workload progression.
Subjects will be supervised by a trained exercise physiologist
and will have continuous telemetry heart rate monitoring using
the Polar heart rate monitor (Polar Electro). Fatigue will be
assessed through rating of perceived exertion via the Borg 6-20
scale; blood pressure will be checked both before and after
exercise as well as periodically during each exercise.
Each exercise training session will be documented with
preexercise and postexercise vital signs, time of day beverage
was consumed, total exercise time, and workload (ie, treadmill
speed and grade) recorded. Body weight and dietary intake will
be assessed on a weekly basis. All research team members
working with the subjects will be blinded to the treatment
intervention and every attempt will be made keep encouragement
and workload adjustment standardized between subjects.
Testing Methodology
Overview
The subjects and research staff conducting the testing will be
unaware of group assignments. The primary investigator will
know to which treatment group the subjects are randomized,
since changes in plasma nitrate and nitrite will be used to
determine beverage volumes and tolerance. Because of the
potential for bias, however, the primary investigator will not be
directly involved in collecting or analyzing any of the exercise
performance or training data.
For all testing visits, participants will be advised to avoid
exercise and consuming alcohol for 24 hours prior to the
examination day. They will also be asked to avoid tobacco and
caffeine for 3 hours prior to any testing or exercise visit.
Maximal Cardiopulmonary Exercise Test
Overview
The maximal cardiopulmonary exercise test (CPX) with a
12-lead electrocardiogram and expired gas analysis will be
conducted using a modified Gardner protocol. This protocol
starts at 2.0 mph and 0.0% grade and increases by 2.0% grade
every 2 minutes at each stage [42].
Prior to commencing the protocol, participants will be
familiarized with the Borg rating of perceived exertion scale as
well as the claudication pain scale. Resting measures of
gastrocnemius tissue oxygenation, via NIRS, and oxygen
consumption, via a metabolic cart, will be recorded.
Throughout the test, heart rate, blood pressure, NIRS, and rating
of perceived exertion will be monitored. Assuming there are no
adverse events, participants will walk on the treadmill until
volitional exhaustion. These participants will likely be limited
by leg claudication pain and, therefore, we expect to attain a
VO2peak, rather than a maximum.
Measures of Pain-Free Walking Time and Maximal Exercise
Capacity
The measure of pain-free walking time will be recorded as the
total time walked prior to the onset of claudication pain. During
the max CPX, participants will be instructed to inform a research
team member when they first feel pain in their leg during
exercise—this will be recorded as COT. PWT will be recorded
as the total time (in seconds) that the participant walked on the
treadmill. VO2peak will be the average of the last 30 seconds of
exercise.
Nitric Oxide Bioavailability Measurement (Plasma Nitrite
Changes)
Prior to beginning the max CPX, a 20-gauge intravenous catheter
will be placed in an antecubital vein. Approximately 5 mL of
blood will be taken prior to the max CPX testing (Pre) and at
10 minutes following exercise termination (Post). Samples will
then be separated into five 1 mL Eppendorf tubes containing 5
µL heparin (1-1000 U/mL) and centrifuged at 5000 g for 3-4
minutes [26]. Afterward, the plasma will be removed into five
separate tubes, snap-frozen in liquid nitrogen, and stored at
-80°C until analysis.
All NO metabolite concentrations will be measured within 30
minutes of defrosting by chemiluminescence using the NOA
280 nitric oxide analyzer (Sievers Instruments) as per the
manufacturer’s instructions. The reductant used for nitrite
analysis will be potassium iodide in acetic acid, which has the
reduction potential to convert nitrite to NO; this reductant is
insufficient to reduce any higher oxides of nitrogen such as
nitrate and, thus, is relatively specific for nitrite. To obtain
concentrations of total plasma nitrogen oxides, we will use the
same apparatus with a stronger reductant, vanadium chloride
in 1 M HCl, at 94°C. This reduces the sum of all nitrogen oxides
with an oxidation state of +2 or higher, which is predominantly
nitrate (µM), but also includes both nitrite (nM) and nitrosothiols
(nM).
Tissue Oxygenation Measurement (Near-Infrared
Spectroscopy)
NIRS has been shown to be a reproducible and reliable method
to determine tissue oxygen stores in human skeletal muscle
tissue [38]. The NIRS PortaMon device (Artinis Medical
Systems) is a noninvasive portable tool for measuring tissue
oxygenation. It works by emitting near-infrared light
wavelengths of 760 nm and 850 nm that correspond to the
absorption spectra of hemoglobin (Hb) and deoxygenated Hb,
respectively. Depending on the oxygenation status of the tissues
(ie, how much oxygenated vs deoxygenated Hb is present), the
resultant spectra will change and the light fraction will be
captured by a detector on the device itself [39]. This technique
provides continuous snapshots of the muscle tissue oxygenation
as well as percent oxygen saturation.
The tissue oxygenation will be assessed utilizing the NIRS
device to obtain an index of fractional oxygen
extraction—[deoxy(Hb + myoglobin)]—and percent oxygen
saturation at rest at the beginning of the exercise test and
continuously monitored throughout the max CPX and recovery
period [26].
Vascular Function
Overview
For the vascular testing visit, subjects will be instructed to
withhold all medications and consume no food for 8 hours prior
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to the exam. All vascular testing will be performed between 8
am and 11 am in a temperature-controlled room following 10-15
minutes of quiet relaxation.
Endothelial Function (Brachial Artery Flow-Mediated
Dilation)
Endothelial dysfunction is a precursor to the development of
atherosclerosis and an independent predictor of cardiovascular
events and clinical outcomes [43]. Brachial artery flow-mediated
dilation is the most commonly used noninvasive measure for
the assessment of endothelial function [44]. This technique
relies on the reactive hyperemic response where there is an
increase in arterial blood flow following a period of ischemia
(ie, occlusion). The dilation of the artery—typically the brachial
artery is imaged—represents, in part, the NO-mediated arterial
response to sheer stress [43,45]. All imaging will be performed
at the brachial artery of the left arm with the subject in a supine
position, with the forearm extended and slightly supinated. All
image captures will be r-wave triggered. Two 10-second
video-captures of the brachial artery will be obtained at baseline
(resting), and then 2 minutes of continuous imaging will be
recorded following 5 minutes of distal forearm occlusion
(reactive hyperemia). Absolute and relative changes in brachial
artery diameter will be calculated as follows:
Absolute and relative changes in brachial artery diameter =
(peak posthyperemia diastolic diameter − baseline diastolic
diameter)/baseline diastolic diameter × 100 (1)
Vascular Stiffness
Central blood pressures—the pressures by which the internal
organs are perfused—have been shown to be strongly related
to clinical outcomes [46]. A specially designed brachial cuff
will be utilized to capture brachial systolic and diastolic pressure
as well as the pulse waveform. The SphygmoCor software
version 8.0 (AtCor Medical) will then use a validated
generalized transfer function to derive central diastolic and
systolic blood pressure, mean arterial pressure and pressure
product along with the pressure augmentation (ΔP) due to wave
reflection, and the pressure augmentation index (AIx):
AIx = ΔP/pulse pressure × 100 (2)
To capture PWV, sequential measurements of arterial pressure
waves will be taken at the carotid artery, using applanation
tonometry, and femoral artery, using a specialized thigh cuff.
The surface distances from the sternal notch to the carotid and
femoral sites will be measured and input into the software for
calculation of the PWV. Pressure wave transit times to each site
will be measured using the foot-of-the-wave method:
Distance of pulse wave (DPW) = sternal notch
distance to femoral artery − carotid artery distance to
sternal notch (3)
Carotid − femoral PWV = DPW/transit time(s) (4)
Ankle-Brachial Index
The ankle-brachial index (ABI) is the ratio of blood pressure
in the feet in comparison to the arms and is linked with mortality
and morbidity rates [47,48]. Measurements will be obtained on
both the left and right side of each subject. A 5-7 MHz handheld
Doppler probe coupled with a BP cuff—positioned proximal
to the probe—will be used to detect blood flow through the
arteries. On each arm, the brachial artery will be occluded at
the biceps using an appropriately sized BP cuff, while the
Doppler probe will be placed over the brachial artery to detect
blood flow. An additional cuff will be placed approximately 3
cm above the medial malleolus in order to occlude the anterior
tibial (AT) artery. The AT artery bifurcates in the foot into the
dorsalis pedis (DP) and the posterior tibialis (PT) arteries, so
both the DP and PT arteries will be measured separately via
Doppler after occlusion of the AT artery using the BP cuff. The
average of the least two separate measurements will be taken
at each artery. The ABI value will be calculated by dividing the
higher average DP or PT value from each side by the highest
average radial artery value obtained from either side [27].
Lower-Limb Blood Flow
Following the ABI procedure, the participant will be kept supine
throughout the plethysmography measurements. Lower-limb
blood flow will be assessed both at rest and following reactive
hyperemia via the use of a Hokanson A16 mercury-in-silastic
strain gauge plethysmograph (Hokanson Inc). Initial setup
requires the patient to lie supine, with the legs elevated slightly
above the level of the heart to facilitate venous emptying. Two
BP cuffs will be placed on the upper thigh of the leg to be
assessed: one will be used for arterial occlusion and one for
venous occlusion. A mercury-in-silastic strain gauge will be
placed around the widest part of the calf to allow for the indirect
measurement of blood flow via changes in lower-limb diameter.
Resting measures will be acquired by inflating and deflating
the venous occlusion thigh cuffs to approximately 50 mmHg
(ie, just above venous pressure) every 10 seconds for five cycles.
During inflation, the mercury-in-silastic strain gauge will be
placed under stress, which will then be graphically represented
as a pressure response curve on the Hokanson A16 machine.
The average of three resting measures will be used as the
baseline arterial inflow measure. Following 5 minutes of rest,
the thigh cuff will be inflated to 30 mmHg above systolic
pressure to induce arterial occlusion for 5 minutes. Upon release
of the occlusion cuff, the same procedure used for resting
measures will be initiated whereby the venous occlusion cuff
will be inflated and deflated to create a pressure response curve
for blood flow following reactive hyperemia [17].
Gastrocnemius Muscle Biopsy
Prior to muscle biopsies, all subjects will be asked to refrain
from anticoagulant medications. Samples from the
gastrocnemius muscle will be obtained using the Bergstrom
percutaneous needle biopsy technique. Biopsy sites will be
anesthetized with a 2% Xylocaine solution and a 0.5 cm incision
will be made through the skin and fascia. Separate samples will
be taken with approximately five passes of the needle into the
muscle. All samples will then be prepared immediately by
weighing and then dividing the samples for later analysis. A
tissue sample of approximately 100 mg is consistently obtained
with a triple pass from a single insertion; we have demonstrated
that this amount of tissue is sufficient for analyzing muscle fiber
composition and angiogenesis. Visible blood and connective
tissue will be removed and the specimens divided longitudinally.
Portions for RNA (40 mg) analyses will be frozen in liquid
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nitrogen and stored at -70°C. Another portion to be used for
histochemical analysis (~30 mg) will be oriented such that the
fibers run longitudinally, mounted on cork-embedding medium
(OCT compound), and frozen in isopentane cooled with liquid
nitrogen.
For the analysis of the muscle tissue, after thawing the tissue,
measurements will be taken for markers of angiogenesis
including the following: capillaries per unit area and per muscle
fiber, endothelial cells with surrounding pericytes, and relative
fraction of type I, IIa, IIb, and IId/x fibers. Additionally,
oxidative capacity of the fibers will be quantified via
mitochondrial volume with citrate synthase activity.
Regulatory Issues
Informed consent has been obtained from each patient and the
study has been approved by the Duke University School of
Medicine Institutional Review Board. The study is being run
under an Investigational New Drug application filed with the
US Food and Drug Administration.
Statistical Analysis Plan
This is a repeated-measures design, with the purpose of assessing
change over time for the two intervention groups. Since this is
a pilot study, the overarching goal of the analyses is to derive
effect sizes (ie, effectiveness) for this intervention for a future
larger, confirmatory study. We will conduct the analyses
chronologically in three phases: (1) descriptive analyses of
dependent and independent variables; (2) bivariate analyses of
the association between group membership and the outcome
measures; and (3) controlled multivariable analyses, which
assess the association between groups and the outcomes
controlling for important covariates. Randomization should
ensure the groups are initially equal; however, we will control
for important baseline variables, including the two outcomes
of interest. We will not control for any variables observed
postrandomization [46]. Our general analytic strategy will be
to employ these models to assess differences between groups
and, most importantly, assess the differences in change over
time between the groups. Our general baseline model will have
the following form:
Y it = β 0 + β 1 (Group) + β 2 (Time t) + β 3 (Group ×
Time t) + β 4 (Covariates it) + ε it (5)
where Yit is the change in the outcome over the time points, t
is an indicator of change period (t=2,4) depending on the wave
of measurement, and i is an indicator of the individual (i=1,24).
β1 is an indicator variable indicating group membership. β2 is
an indicator variable indicating the time of testing: baseline,
baseline on supplement, postintervention on supplement, and
postintervention off supplement. β3 is a Group × Timet
interaction. As listed, β4 is a vector of regression weights linking
the design matrix of covariates—time varying and time
invariant—to the outcome of interest. We will center Timet=0
at the final 12-week time point, which will allow us to test if
there are differences at the end of the trial, β1=0. Follow-up
analyses will assess the impact of Group × Timet interaction
and the functional form of the change over time. Inclusion of
covariates into the model, including baseline measures, may
add precision to the estimates and allow us to assess the
generalizability of the effects across the covariates. The list of
covariates (eg, age, gender, health events, comorbidity, and
medications) will be developed prior to any analysis. This is a
small sample (n=24); hence, the number of covariates we can
utilize in any regression is minimal: ≈10 cases per variable [47].
We will assess the impact of each potential covariate
individually without respect to group and, if significant (P=.10),
it will be retained in models with Group, Timet, and Group ×
Timet (see above).
This is a pilot study and we do not expect to declare statistical
significance for any of the variables assessed under this analytic
structure. However, if the target 12 subjects per group is
attained—EX+BR and EX+PL; 24 total subjects—and if a power
of 80% with alpha set to .05 (two-tailed) is used, then we will
be able to detect a 0.826 standardized difference in the difference
in the change labeled as “large” in the statistical power literature
[49]. We will not control for the type I error risk inherent in
testing multiple outcomes. Rather, should any outcome be
declared significant, the reader will be alerted to the number of
tests performed and the risk in drawing definitive conclusions
with multiple outcomes and a small sample size.
As noted previously, the results from this pilot study will be
used to power a subsequent, larger, adequately powered
confirmatory clinical trial of the impact of beetroot juice on the
outcomes listed above. The results, along with theory and
clinical significance, will guide the choice of the primary
outcome(s) for that trial, with appropriate control for type I
error. While the results of this pilot study will prove useful in
the calculation of power, we are aware of the many risks of
“playing the winner” in choosing to power a subsequent trial
from pilot study results only [50,51].
Results
Data collection from this study has been completed and is in
the process of analysis and write-up. While the study is too
underpowered—EX+BR, n=11; EX+PL, n=13—to determine
between-group differences in the primary outcomes of COT,
PWT, and 6MW, preliminary observations are promising with
Cohen d effect sizes of medium to large.
Discussion
Principal Findings
Improving pain-free walking and exercise capacity are key goals
for the treatment and rehabilitation of patients with peripheral
arterial disease [1]. This study aims to determine if the combined
intervention of the current best treatment for PAD (ie, supervised
exercise training) in conjunction with inorganic nitrate
supplementation using beetroot juice can increase exercise
tolerance more than exercise training alone (ie, placebo
supplement).
The physiological basis for this trial relies on the fact that
supplementation with inorganic nitrate will lead to increased
plasma nitrite that can be transported throughout the circulation
and is reduced to NO in tissue with a low partial pressure of
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oxygen. This hypoxic tissue-targeting effect may be particularly
pertinent for patients with PAD+IC experiencing tissue ischemia
during exercise participation. While it is well established that
consuming inorganic nitrate increases circulating levels of
plasma nitrite [28,52], research on the corresponding effect on
key clinical outcomes such as exercise performance in clinical
patients, while promising, is still limited [27,38,39].
There are three mechanisms that lend support to nitrate
supplementations’ clinical utility in improving exercise
performance in patients with PAD. First, acute supplementation
data suggest that increasing plasma nitrite via beetroot juice
improves ischemic tissue perfusion leading to increases in
pain-free walking time and aerobic function [27]. Second,
increased exercise time or intensity will facilitate greater training
responses and tissue adaptations. Third, increased bioavailability
of NO could lead to a greater tissue angiogenic response. These
mechanisms are complementary to each other and may result
in a greater overall exercise tolerance
Study Limitations
The small sample size and the focus on patients with PAD+IC
only limit the ability to broadly apply the results of the study
to the larger PAD population and to generalize these results to
subsequent studies. This study also uses a per-protocol design
with the intent that data may provide the physiological proof of
concept for the intervention and allow us to derive variance data
and effect sizes within and between groups to inform future
studies, which will utilize an intent-to-treat criterion in the
analytic structure.
Potential Impact
This study has been designed to investigate a new therapeutic
approach for the treatment of PAD+IC. If successful, the results
could influence current medical practice for these patients, while
also providing mechanistic insights into potential physiologic
targets for other interventions. Research clearly identifies
supervised exercise training as being one of the most effective
interventions for improving exercise tolerance in patients with
PAD [1,53,54]. We hypothesize the combination of
supplementation with exercise will create greater adaptations
than the sum of the individual exposures alone. If true, the
findings would lead to a paradigm shift in the treatment
recommendations for patients with PAD.
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Abbreviations
6MW: 6-minute walk
ABI: ankle-brachial index
AIx: augmentation index
AT: anterior tibial
BP: blood pressure
BR: beetroot
COT: claudication onset time
CPX: cardiopulmonary exercise test
ΔP: pressure augmentation
DP: dorsalis pedis
DPW: distance of pulse wave
EX+BR: exercise training plus beetroot juice
EX+PL: exercise training plus placebo juice
Hb: hemoglobin
IC: intermittent claudication
max CPX: maximal-graded cardiopulmonary exercise test
NIRS: near-infrared spectroscopy
NO: nitric oxide
NO2-: nitrite
NO3-: nitrate
PAD: peripheral artery disease
PAD+IC: peripheral artery disease with intermittent claudication
PL: placebo
PT: posterior tibialis
PWT: peak walk time
PWV: pulse wave velocity
VO 2peak: peak oxygen uptake
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